Heron Therapeutics (HRTX) to Release Earnings on Thursday

Heron Therapeutics (NASDAQ:HRTX) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $39.5330 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Heron Therapeutics Stock Down 8.4%

Shares of NASDAQ HRTX opened at $1.09 on Wednesday. The company has a market capitalization of $199.86 million, a P/E ratio of -12.11 and a beta of 1.25. Heron Therapeutics has a 1 year low of $1.00 and a 1 year high of $2.68. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78. The company has a 50 day simple moving average of $1.31 and a 200-day simple moving average of $1.27.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Heron Therapeutics by 19.3% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 13,544 shares during the last quarter. Glenmede Investment Management LP boosted its holdings in shares of Heron Therapeutics by 49.9% during the third quarter. Glenmede Investment Management LP now owns 105,326 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 35,076 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of Heron Therapeutics during the 2nd quarter valued at about $99,000. State of Wyoming acquired a new position in shares of Heron Therapeutics in the 4th quarter valued at $76,000. Finally, Prudential Financial Inc. grew its position in Heron Therapeutics by 231.0% during the second quarter. Prudential Financial Inc. now owns 36,465 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 25,450 shares during the period. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Wall Street Analyst Weigh In

HRTX has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.50.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.